Back to Journals » OncoTargets and Therapy » Volume 11

Therapy-related myeloid neoplasms: clinical perspectives

Authors Fianchi L, Criscuolo M, Fabiani E, Falconi G, Maraglino AME, Voso MT, Pagano L

Received 14 August 2017

Accepted for publication 19 May 2018

Published 17 September 2018 Volume 2018:11 Pages 5909—5915


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Samir Farghaly

Luana Fianchi,1 Marianna Criscuolo,1 Emiliano Fabiani,2 Giulia Falconi,2 Alessio Maria Edoardo Maraglino,1 Maria Teresa Voso,2 Livio Pagano1

1Department of Radiological Sciences, Radiotherapy, and Hematology, Fondazione Policlinico Universitario A. Gemelli, IRCCS, Rome, Italy; 2Department of Biomedicine and Prevention, Università di Roma Tor Vergata, Rome, Italy

Abstract: Therapy-related myeloid neoplasms (t-MNs) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. t-MNs result from a complex interaction between individual predisposition and exposition to toxic agents. Some different biological and clinical characteristics can be recognized according to the type of anticancer drug. Compared to de novo myeloid neoplasms, prognosis of t-MN is dismal. Age and karyotype are the most important prognostic factors for t-MN, which should be treated with frontline chemotherapy treatments that are appropriate for patients with myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) with similar disease characteristics. Allogeneic stem cell transplantation should be considered particularly for unfavorable karyotypes and younger patients with aggressive disease.

Keywords: therapy-related myeloid neoplasm, leukemia, prognosis, secondary leukemia, secondary myelodysplastic syndrome

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]